The study developed a validated non-invasive model (RS-BTIplusVPE) based on integrating BTI-based radiomics features and VPE, which showed improved prediction of EGFR-TKI response in NSCLC patients with BM compared to tumor-focused models. The gene discussed is EGFR; the disease is neoplasm.